Catabasis Shares Its Latest Edition of Catabasis Connection

March 15, 2022

Catabasis Pharmaceuticals’ Phase 3 PolarisDMD trial is enrolling the expected patient population and they are partnering with Duchenne UK to evaluate edasalonexent in non-ambulatory boys and men affected by Duchenne. Read all about these activities and more in their latest newsletter here. You can hear directly from them in person at our Worcester Family Workshop on January 25, 2020. Register for the workshop today.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open